This project aims to be the first to empirically assess the utilization of available genetic tests nationally. Cancer genetics is one of the most active and successful areas of genomic medicine with several clinical applications in widespread use to tailor cancer prevention and treatment. Thus, cancer genetics is the ideal place to start in expanding national capacity to track the diffusion of genomic medicine and the impact of genetically-tailored prevention and treatment on vulnerable populations. Through this project, we will develop strategies for using large, national administrative databases to track the diffusion and clinical impact of genetically-tailored cancer prevention and treatment, with a focus on disparities (by race/ethnicity and insurance type/status) in access to available genetic tests and appropriate follow-up care.
- Alexandra E. Shields, Ph.D.
- Kevin Weiss, M.D.
- William Crown, Ph.D.
- Douglas Levy, Ph.D.
- Christine Vogeli, Ph.D.
- Levy D.E., Garber J.E., Shields A.E. Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization. Journal of General Internal Medicine. 2009; Jul 24(7):822-8. PMID: 19455369.
- Levy D.E., Byfield S.D., Comstock C.B., Garber J.E., Syngal S., Crown W.H, Shields A.E. Underutilization of BRCA1/2 Testing to Guide Breast Cancer Treatment: Black and Hispanic Women Particularly at Risk. Genetics in Medicine. 2011; Apr:13(4)349-55. PMID: 21358336.